Article
Boehringer Ingelheim advances obesity drug candidate with up to 19% weight loss in mid-stage trial
Rating:
0.0
Views:
17
Likes:
1
Library:
1
German pharmaceutical company Boehringer Ingelheim revealed its intention to launch three advanced-stage investigations into its promising obesity drug candidate.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value